Literature DB >> 10968800

The future of research into rotavirus vaccine.

C Weijer.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10968800      PMCID： PMC1118429          DOI： 10.1136/bmj.321.7260.525

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  Intussusception among recipients of rotavirus vaccine--United States, 1998-1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-07-16       Impact factor: 17.586

Review 2.  The magnitude of the global problem of diarrhoeal disease: a ten-year update.

Authors:  C Bern; J Martines; I de Zoysa; R I Glass
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

3.  Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries.

Authors:  P Lurie; S M Wolfe
Journal:  N Engl J Med       Date:  1997-09-18       Impact factor: 91.245

4.  The ethics of clinical research in the Third World.

Authors:  M Angell
Journal:  N Engl J Med       Date:  1997-09-18       Impact factor: 91.245

5.  Human rotavirus infection in infants and young children with intussusception.

Authors:  T Konno; H Suzuki; T Kutsuzawa; A Imai; N Katsushima; M Sakamoto; S Kitaoka; R Tsuboi; M Adachi
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

6.  Equipoise and the ethics of clinical research.

Authors:  B Freedman
Journal:  N Engl J Med       Date:  1987-07-16       Impact factor: 91.245

7.  Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Authors: 
Journal:  MMWR Recomm Rep       Date:  1996-09-06

8.  Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela.

Authors:  I Pérez-Schael; M J Guntiñas; M Pérez; V Pagone; A M Rojas; R González; W Cunto; Y Hoshino; A Z Kapikian
Journal:  N Engl J Med       Date:  1997-10-23       Impact factor: 91.245

9.  Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group.

Authors:  D I Bernstein; R I Glass; G Rodgers; B L Davidson; D A Sack
Journal:  JAMA       Date:  1995-04-19       Impact factor: 56.272

10.  Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.

Authors:  M B Rennels; R I Glass; P H Dennehy; D I Bernstein; M E Pichichero; E T Zito; M E Mack; B L Davidson; A Z Kapikian
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124
View more
  10 in total

1.  Future of research into rotavirus vaccine. Cost effectiveness of vaccine is being assessed.

Authors:  D Walker; S M Akramuzzaman; C F Lanata
Journal:  BMJ       Date:  2001-01-13

2.  Perspectives on benefit-risk decision-making in vaccinology: Conference report.

Authors:  M Greenberg; F Simondon; M Saadatian-Elahi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  Risk-benefit analysis: from a logical point of view.

Authors:  Georg Spielthenner
Journal:  J Bioeth Inq       Date:  2012-03-21       Impact factor: 1.352

4.  Molecular epidemiology of rotaviruses in Nigeria: detection of unusual strains with G2P[6] and G8P[1] specificities.

Authors:  M I Adah; A Wade; K Taniguchi
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

5.  Human-animal chimeras for vaccine development: an endangered species or opportunity for the developing world?

Authors:  Anant Bhan; Peter A Singer; Abdallah S Daar
Journal:  BMC Int Health Hum Rights       Date:  2010-05-19

Review 6.  The first rotavirus vaccine and the politics of acceptable risk.

Authors:  Jason L Schwartz
Journal:  Milbank Q       Date:  2012-06       Impact factor: 4.911

7.  Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.

Authors:  Andrew Clark; Jacqueline Tate; Umesh Parashar; Mark Jit; Mateusz Hasso-Agopsowicz; Nicholas Henschke; Benjamin Lopman; Kevin Van Zandvoort; Clint Pecenka; Paul Fine; Colin Sanderson
Journal:  Lancet Glob Health       Date:  2019-11       Impact factor: 26.763

8.  Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis.

Authors:  Manish M Patel; Andrew D Clark; Colin F B Sanderson; Jacqueline Tate; Umesh D Parashar
Journal:  PLoS Med       Date:  2012-10-23       Impact factor: 11.069

9.  Balancing safety, efficacy and cost: Improving rotavirus vaccine adoption in low- and middle-income countries.

Authors:  Anant Bhan; Shane K Green
Journal:  J Glob Health       Date:  2011-12       Impact factor: 4.413

10.  Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule.

Authors:  Ruha Shadab; James V Lavery; SarahAnn M McFadden; Jad A Elharake; Fauzia Malik; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2021-05-19       Impact factor: 3.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.